Economic impact on direct healthcare costs of missing opportunities for diagnosing HIV within healthcare settings.

BACKGROUND: The economic consequences of a missed opportunity for HIV testing at an earlier stage of infection within a healthcare setting are poorly described. METHODS: For all newly diagnosed HIV patients followed at the Southern Alberta HIV/AIDS Clinic (SAC), Calgary, Canada, between 1 April 2011 and 1 April 2016, all clinical encounters occurring < 3 years prior to diagnosis within the region were obtained. The direct costs of HIV care after diagnosis to 31 March 2019 were determined from a payers' perspective and reported as mean cost per patient per month (PPPM) in 2019 Canadian dollars (CDN$). Patients with no encounters for 3 years prior to diagnosis were compared with patients with encounters, with special attention to patients with HIV clinical indicator conditions (HCICs). RESULTS: Of 388 patients, 60% had one or more prior encounter without HIV testing; 14% had been treated for an HCIC. Females, older patients and heterosexuals were more likely to have prior encounters. At diagnosis, patients with previous encounters presented with lower CD4 counts and higher rates of AIDS. The mean PPPM costs for patients with any prior encounter or for an HCIC-based encounter were 16% and 33% higher, respectively, than for patients with no prior encounters. While mean PPPM costs for antiretroviral drugs and outpatient visits were slightly higher, in-patient costs were 10 times higher for people with HIV who had a previous HCIC encounter vs. those with no encounters (CDN$316 vs. $31, respectively). CONCLUSIONS: Any healthcare visit, especially for an HCIC, represents relatively easy opportunities for HIV testing. Not testing can result in poorer health and higher costs. Targeted clinical testing and novel interventions to correct overlooked testing opportunities within healthcare settings may be an easy way to implement cost savings.

Updated direct costs of medical care for HIV-infected patients within a regional population from 2006 to 2017.

OBJECTIVES: The aim of the study was to reappraise the precise costs of HIV care and cost drivers, to determine the optimal tools for modelling costs for HIV care, and to understand the implications of changing medical management of HIV-infected patients for both subsequent outcomes and health care budgets. METHODS: We obtained all drug, laboratory, out-patient and in-patient care costs for all HIV-infected patients followed between 1 January 2006 and 31 December 2017 (2017 Cdn$). Mean cost per patient per month (PPPM) was used as the standard comparator value. Patients were stratified based on CD4 count: (1) ≤ 75, (2) 76-200, (3) 201-500 and (4) > 500 cells/µL. We determined the cost for only HIV-related expenses. We compared current costs with costs previously reported for the same population. RESULTS: The number of HIV-infected patients in care doubled from 2006 to 2017; total costs increased from $12.4 to $30.1 million, with antiretroviral (ARV) drugs accounting for 78.8% of costs by 2017. Out-patient/laboratory costs declined from 12% to 8.5%, while in-patient costs exhibited more annual variation. Mean PPPM costs increased from $1316 in 2006 to $1712 in 2014, declining to $1446 in 2017. Higher PPPM costs were associated with CD4 counts < 200 cells/µL. Costs have shifted. While the cost of ARV drugs increased by 32%, the costs of out-patient and in-patient services decreased by 80% and 71%, respectively. Most of the decrease for in-patient costs was attributable to a substantial decrease in HIV-related hospitalizations. CONCLUSIONS: Although antiretroviral therapy (ART) provides immense benefits, it is not inexpensive. ARV drugs remain the largest cost driver. Hospital costs have remained low. Substantial costs of lifelong ART necessitate innovative, locally applicable strategies for ARV selection and use.

De-simplifying single-tablet antiretroviral treatments: uptake, risks and cost savings.

OBJECTIVES: As more HIV-positive individuals receive antiretroviral therapy (ART), payers are seeking options for covering these increased and sustained drug costs. Strategic use of available generic antiretroviral (ARV) formulations may be feasible. De-simplifying a single-tablet co-formulation (STF) into two or more tablets using both brand and generic drugs has been proposed. We determine if voluntary de-simplification of one STF could be utilized as a cost-saving strategy. We report on the challenges, uptake, outcomes and cost savings of this initiative. METHODS: Patients stable on the most commonly used STF (Triumeq® ) were offered the option of remaining on Triumeq® or switching to generic abacavir/lamivudine and Tivicay® between 1 January 2015 and 1 January 2018; those starting ART consisting of abacavir/lamivudine/doulutegravir in the same period were offered the option of starting Triumeq® or generic abacavir/laminvudine and Tivicay® . No incentives were provided. We examined the acceptance/decline rates, patient satisfaction, health care outcomes and annual cost savings. RESULTS: Of 626 patients receiving Triumeq® , 321 were approached; 177 (55.1%) agreed to de-simplify. Of patients initiating ART, 62.7% chose the generic co-formulation. Patients switching to or starting on the generic co-formulation were more likely to be male, > 45 years old, Caucasian, men who have sex with men (MSM) and more HIV-experienced, and to have more comorbidities (all P < 0.05). Preference for STF was cited for declining de-simplification. No concern about generic ARVs was expressed. The rate of viral load > 500 HIV-1 RNA copies/mL after baseline was 2.7% in switched patients compared with 7.0% in those declining to switch. No de novo resistance occurred. A saving of Cdn$1 319 686 was achieved in the first year. CONCLUSIONS: Reliance on altruism, while respecting patient autonomy, achieved de-simplification in > 50% of patients approached, and generated immediate cost savings with no increased risk of adverse events, viral breakthrough or resistance.

Patient perspectives on de-simplifying their single-tablet co-formulated antiretroviral therapy for societal cost savings.

OBJECTIVES: The incremental costs of expanding antiretroviral (ARV) drug treatment to all HIV-infected patients are substantial, so cost-saving initiatives are important. Our objectives were to determine the acceptability and financial impact of de-simplifying (i.e. switching) more expensive single-tablet formulations (STFs) to less expensive generic-based multi-tablet components. We determined physician and patient perceptions and acceptance of STF de-simplification within the context of a publicly funded ARV budget. METHODS: Programme costs were calculated for patients on ARVs followed at the Southern Alberta Clinic, Canada during 2016 (Cdn$). We focused on patients receiving Triumeq® and determined the savings if patients de-simplified to eligible generic co-formulations. We surveyed all prescribing physicians and a convenience sample of patients taking Triumeq® to see if, for budgetary purposes, they felt that de-simplification would be acceptable. RESULTS: Of 1780 patients receiving ARVs, 62% (n = 1038) were on STF; 58% (n = 607) of patients on STF were on Triumeq®. The total annual cost of ARVs was $26 222 760. The cost for Triumeq® was $8 292 600. If every patient on Triumeq® switched to generic abacavir/lamivudine and Tivicay® (dolutegravir), total costs would decrease by $4 325 040. All physicians (n = 13) felt that de-simplifying could be safely achieved. Forty-eight per cent of 221 patients surveyed were agreeable to de-simplifying for altruistic reasons, 27% said no, and 25% said maybe. CONCLUSIONS: De-simplifying Triumeq® generates large cost savings. Additional savings could be achieved by de-simplifying other STFs. Both physicians and patients agreed that selective de-simplification was acceptable; however, it may not be acceptable to every patient. Monitoring the medical and cost impacts of de-simplification strategies seems warranted.

Increased costs of HIV care associated with aging in an HIV-infected population.

OBJECTIVES: Improved survival has shifted the HIV epidemic in the developed world towards more individuals >50 years of age. Older individuals, with new or longstanding HIV infection, are at greater risk for HIV-related and non-HIV-related conditions, compounding the burden and complexity of HIV management. The aim of the study was to examine the impact of age on the cost of HIV care in a well-defined HIV-infected population. METHODS: All HIV-infected individuals >16 years old receiving HIV care between 1 January 2000 and 1 January 2011 were included in the study. The costs of antiretroviral therapy (ART), HIV-related out-patient care and HIV-related in-patient care were collected using mean cost per person, per month (PPPM) as the comparator variable for the comparison between older (>50 years old) and younger (≤ 50 years old) patients. RESULTS: The proportion of older patients increased from 9.6% to 25.4% and proportional costs increased from 25% to 31% from 1999 to 2010. Older patients were more likely than younger patients to be on ART (89% vs. 69%, respectively; P<0.01) and to have AIDS (29% vs. 20%, respectively; P<0.05) but had similar median CD4 counts (404 vs. 396 cells/µL, respectively; not significant). They incurred higher costs for all aspects of HIV care throughout the entire 12 years. By 2010, the mean PPPM cost of HIV care for longstanding older patients was $1325 compared with $1075 for younger patients. More expensive ART as a consequence of more complex regimens, more comorbid interactions and greater adherence accounted for most of the cost difference. CONCLUSIONS: The aging of the HIV-infected population in care is leading to increased HIV care costs. Health care planners and funding agencies need to be aware of the impact of this important shift in HIV demographics on the overall costs of HIV care.

Prevalence, clinical associations, and impact of intimate partner violence among HIV-infected gay and bisexual men: a population-based study.

OBJECTIVES: Intimate partner violence (IPV) is a risk factor for HIV infection. Little is known, however, about the prevalence, clinical associations, and impact of IPV among patients living with HIV. METHODS: HIV-infected gay and bisexual men in Southern Alberta, Canada were screened for IPV between May 2009 and December 2011. The associations with IPV of sociodemographic factors, psychological factors, clinical status, and HIV-related and HIV-unrelated hospitalizations, data for which were obtained from a regional database, were evaluated using Poisson regression. RESULTS: Of 687 gay and bisexual patients, 22.4% had experienced one or several types of IPV. Patients disclosing IPV were more likely to be Aboriginal [adjusted prevalence ratio (APR) = 2.48; 95% confidence interval (CI) 1.18-5.20], to be younger (APR/year = 0.97; 95% CI 0.95-0.99), to be victims of childhood abuse (APR = 4.27; 95% CI 2.84-6.41), to be smokers (APR = 2.53; 95% CI 1.59-4.00), to have had depression prior to HIV diagnosis (APR = 1.87; 95% CI 1.10-3.16), to use ongoing psychiatric resources (APR = 3.53; 95% CI 2.05-6.10), to have recently participated in unprotected sex (APR = 2.29; 95% CI 1.10-4.77), and to have poor or fair vs. very good or excellent health-related quality of life (APR = 2.91; 95% CI 1.57-5.39). IPV was also associated with a higher rate of clinically relevant interruptions in care (APR = 1.95; 95% CI 1.23-3.08), a higher incidence of AIDS among patients presenting early to care (CD4 count ≥ 200 cells/µL; APR = 2.06; 95% CI 1.15-3.69), and an increased rate of HIV-related hospitalizations [relative risk (RR) = 1.55; 95% CI 0.99-2.33], especially after HIV diagnosis was established (RR = 2.46; 95% CI 1.51-3.99). CONCLUSIONS: The prevalence of IPV is high among HIV-infected gay and bisexual men and is associated with poor social, psychiatric, and medical outcomes. IPV is an under-recognized social determinant of health in this community that may be amenable to meaningful clinical interventions.

On the variability in preterm birth rate, birth weight, and somatic classification among neonates of mothers with the same body mass index.

BACKGROUND: Maternal height and weight are important determinants of perinatal outcomes.Height and weight can be combined in the measure of body mass index (BMI). We aimed to investigate the utility of maternal BMI as a predictor of perinatal outcomes. MATERIALS AND METHODS: Based on data collected between 1995 and 2000 as part of the German perinatal survey, we examined singleton pregnancies of women with BMIs of 18, 24, or 30. We compared preterm birth rate, birth weight, and the somatic classification of neonates as small,appropriate, or large for gestational age (SGA,AGA, LGA) for women with heights of 150 cm and 180 cm for each BMI. RESULTS: For women with a BMI of 18 (24; 30)and a height of 150 cm, the preterm birth rate was 13.9 % (9.1 %; 12.5 %); for women with the same BMI and a height of 180 cm the preterm birth rate was 12.1 % (6.1 %; 4.4 %). Birth weight for women with a BMI of 18 (24; 30) and a height of 150 cm was 2 889 g (3 170 g; 3 147 g); for women with the same BMI and a height of 180 cm it was 3 314 g (3 629 g; 3 753 g). The LGA rate for women with a BMI of 18 (24; 30) and a height of 150 cm was 2.1 % (5.2 %; 5.2 %); for women with the same BMI and a height of 180 cm it was 7.7 %(20.5 %; 27.7 %). CONCLUSIONS: There is considerable variability in perinatal outcomes between women with the same BMI but different heights. This limits the utility of BMI as a predictor of perinatal outcomes.

Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study.

BACKGROUND: Combination antiretroviral therapy (cART) has improved the survival of patients with HIV/AIDS but its impact remains uncertain on the changing prevalence and incidence of neurologic disorders with ensuing effects on mortality. METHODS: The prevalence and incidence of neurologic disorders were examined in patients receiving active care in a regional HIV care program from 1998 to 2008. The mortality hazard ratio (HR) was calculated by Cox proportional hazard models with adjustment for demographic and clinical variables. RESULTS: Of 1,651 HIV-infected patients assessed, 404 (24.5%) were identified as having one or more neurologic disorders, while 41% of AIDS-affected persons exhibited neurologic disease. Symptomatic distal sensory polyneuropathy (DSP, 10.0%) and HIV-associated neurocognitive disorder (HAND, 6.2%) represented the most prevalent disorders among 53 recognized neurologic disorders. Patients with at least one neurologic disorder exhibited higher mortality rates (17.6% vs 8.0%, p < 0.0001), particularly AIDS-related deaths (9.7% vs 3.2%, p < 0.0001), compared with those without neurologic disorders. The highest mortality HR was associated with opportunistic infections of CNS (HR 5.3, 95% confidence interval [CI] 2.5-11.2), followed by HAND (HR 3.1, 95% CI 1.8-5.3) and the presence of any neurologic disorder (HR 2.0, 95% CI 1.2-3.2). The risk of AIDS-related death with a neurologic disorder was increased by 13.3% per 100 cells/mm(3) decrement in blood CD4+ T-cell levels or by 39% per 10-fold increment in plasma viral load. CONCLUSIONS: The burden and type of HIV-related neurologic disease have evolved over the past decade and despite the availability of cART, neurologic disorders occur frequently and predict an increased risk of death.

Unappreciated epidemiology: the churn effect in a regional HIV care programme.

High levels of geographic mobility in and out of HIV care centres (i.e. the churn effect) can disrupt the continuity of patient care, misalign prevention services, impact local prevalence data perturbing optimal allocation of resources, and contribute to logical challenges in repeated transfer of health records. We report on the clinical, demographic, and administrative impact of high population turnover within HIV populations.

Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.

OBJECTIVES: To report on the cost of medical care for HIV-infected patients stratified by CD4 cell count for a regional population over a 9-year period, and to examine the effect of reporting costs of HIV care only or only in antiretroviral therapy (ART)-experienced patients. METHODS: Retrospective costing analysis on all HIV-infected patients within the Southern Alberta Cohort from April 1997 to April 2006. Costs for all drugs (ART/non-ART), in-patient (HIV/non-HIV) and out-patient care were obtained from primary sources. Costs were aggregated by patient's CD4 cell count and ART exposure and presented as mean cost per patient per month (PPPM) in 2006 Canadian dollars. RESULTS: The number of patients and annual costs increased by 74% and 69%, respectively. Overall mean PPPM costs increased slightly from $1082 in 1997/1998 to $1159 in 2005/2006. PPPM costs for patients with CD4 counts < or =75 cells/microL increased from $1595 to $2687 while costs for CD4 counts >500, 201-500 and 76-200 cells/microL remained relatively stable at $979, $1057 and $1294, respectively. In-patient hospitalization costs account for most of the cost increases. Reporting costs using only ART-experienced patients would overestimate total costs by 2-9%. Costs for only HIV care were 10-24% lower than total care costs. CONCLUSIONS: Care costs have remained relatively stable for most HIV patients except those with CD4 counts < or =75 cells/microL. Expensive new antiretroviral drugs have had, at present, a minimal cost impact. Enhanced testing to achieve earlier diagnosis and initiation of highly active antiretroviral therapy could potentially reduce costs of late presentation and in-patient care.

[Results from a survey of intensive care training. How much that is learned applies to later practice?]. / Umfrageergebnisse zur Ausbildung Intensivmedizin. Was lernt der angehende Chirurg für sein späteres Berufsleben?

BACKGROUND: There is no doubt that good knowledge of intensive care medicine is necessary for any surgeon, since major surgery entails postoperative intensive care requiring the surgeon's involvement. Recent changes in the German surgical training program, demands for the board examination, and further specialisation have raised the question whether the time spent in ICU education is still adequate and covers topics for young surgeons attendant to their personal professional aims. The present survey was performed to elucidate this topic. METHODS: Questionnaires were sent to 300 randomly chosen surgical residents. RESULTS: Of the questionnaires, 44% were returned and eligible for analysis: 95% considered their ICU education important, 32% worked longer than the (required) 6 months on the ICU, and 62% thought the time spent on ICU was adequate, whereas 14.5% thought it too long. Most of these fellows (84%) worked in university hospitals of large medical centers. After their ICU rotation, the majority felt familiar with the basic procedures and regarded them important also for future work. More advanced techniques (e.g. specifics of artificial ventilation or invasive haemodynamic monitoring) were considered less relevant or not at all. CONCLUSION: The majority of fellows (95%) considered ICU training important, but 50% felt that advanced ICU techniques were not relevant to their planned future work as surgeons. Especially in university hospitals and large medical centers, there were discrepancies between proposed and actually served ICU time as well as between the training program and the methods and techniques the young surgeons felt important for the future. This information may be useful when discussing requirements of surgical education programs.

Longitudinal assessment (1995-2003) of hospitalizations of HIV-infected patients within a geographical population in Canada.

OBJECTIVES: To determine the frequency of and reasons for hospitalization of adult HIV-infected patients compared with the general population. METHODS: Length of stay, primary/secondary diagnoses and discharge status were reviewed for all HIV-infected patients admitted to Calgary-area hospitals between 1995 and 2003. Admissions were classified as HIV- or non-HIV-related using International Classification of Diseases, 9th and 10th revisions (ICD-9/10) codes and confirmed by chart review. Summary comparative data on admissions for the general population were obtained from the regional administrative database. RESULTS: HIV-infected adults were hospitalized more than twice as frequently, experienced longer stays (median length 5 vs 3 days, respectively) and had higher in-hospital mortality rates (9.1 vs 1.3 per 100 admissions, respectively) than the general population (P < 0.01). Hospitalizations of HIV-infected patients declined by 58% from 1995 to 2003. Patients newly diagnosed with HIV infection accounted for 15% of all HIV-related hospitalizations. HIV-related admissions for known HIV-infected patients decreased from 12 per 100 patient-years-followed in 1995 to 3 per 100 patient-years-followed in 2003. Low CD4 counts, AIDS, and no current use of highly active antiretroviral therapy (HAART) were strongly correlated with hospitalizations (P < 0.01). Non-HIV-related hospitalizations for HIV-infected patients increased by 42% and were associated with comorbidities (e.g. substance use and psychological disorders). CONCLUSION: Despite the reduction in HIV-related hospitalizations following the introduction of HAART, all-cause hospitalization rates have increased and have started to erode this benefit.

[Accuracy of the autorefractor power refractor in clinical work--a comparative study]. / Messgenauigkeit des Autorefraktometers Power-Refractor in der klinischen Praxis -- eine vergleichende Studie.

BACKGROUND: The aim of this prospective study was to investigate accuracy and efficiency of the autorefractometer PowerRefractor compared to established autorefractometers and retinoscopy as standard method. PATIENTS AND METHODS: 150 patients (300 eyes) were examined. Patients were initially (pupil not influenced) analyzed with the Power Refractor (PR (neutral)). After that a examination followed under standardized Cyclopentolat cycloplegia with the Power Refractor (PR (cyclo)), the hand-held Retinomax K-plus (Nikon), the table-top mounted RK-5 (Canon) and retinoscopy. RESULTS: Deviation from retinoscopy (percentage of values with more than 1 dpt difference/maximal deviation): Sphere: PR (neutral): 66.3 %/8.5 dpt; PR (cyclo): 48 %/5 dpt; RK-5: 26.7 %/4.75 dpt; Retinomax K-plus: 6.7 %/1.25 dpt; Cylinder: PR (neutral): 12 %/6.25 dpt; PR (cyclo): 21 %/4.75 dpt; RK-5: 1.3 %/2.75 dpt; Retinomax K-plus: 2.3 %/2.5 dpt; spherical equivalent: PR (neutral): 44.7 %/7.1 dpt; PR (cyclo): 35.3 %/5.4 dpt; RK-5: 9 %/4.5 dpt; Retinomax K-plus: 1.3 %/1.,4 dpt; error of entire refraction: PR (neutral): 62.7 %/7.8 dpt; PR (cyclo): 61.3 %/7.3 dpt; RK-5: 24 %/4,5 dpt; Retinomax K-plus: 14.7 %/3.6 dpt CONCLUSIONS: The best accuracy compared to retinoscopy had Retinomax K-plus followed by RK-5. PowerRefractor had the biggest deviations of the tested devices. PowerRefractor may be a usefull device for screening small children and handicapped people because of the one meter observing distance. For a precise refraction especially in children a retinoscopy under cycloplegic conditions is still necessary.

Socio-economic factors and health-related quality of life in adults living with HIV.

This study examined the relationships of income, employment status and other socioeconomic characteristics with dimensions of health-related quality of life (HRQOL) for those living with HIV/AIDS, controlling for clinical characteristics. Demographic (gender, age, education, living with a partner, HIV transmission category), economic (employment status, monthly household income, volunteer experience), clinical (CD4 count, AIDS defining illness, time since diagnosis, number of HIV symptoms, and highly active antiretroviral therapy), and HRQOL measures (five Medical Outcomes Study HIV Health Survey subscales) were obtained from 308 consenting HIV clinic patients in Calgary, Canada. Multiple regression results indicate that the strongest predictor of the five QL subscales is employment status, while income was significant as an independent predictor in two of the models. Other socioeconomic characteristics were not consistently significant predictors of HRQOL subscales. The contribution of employment to HRQOL is important to explore further, and suggest the need for flexibility in income support and return-to-work programmes for those with HIV.

Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.

OBJECTIVES: To examine changes over a 2-year period in both the mortality rate and the causes of death in a geographically defined HIV-infected population. METHODS: A database search of primary care information for the dates and causes of death for all patients documented with HIV infection and living in Southern Alberta between 1984 and 2003 was undertaken. Sociodemographic and clinical characteristics were obtained. Causes of death were then individually confirmed by reviewing the patients' hospital charts, autopsy reports, or death certificates and coded using the International Classification of Diseases, 9th Revisions. AIDS deaths were reconciled with Public Health Reports. The time span was divided into pre-highly active antiretroviral therapy (HAART) (1984-1996) and current HAART (1997-2003) periods. RESULTS: Between 1984 and 2003, there were 560 deaths in the 1987 individuals living with HIV infection in Southern Alberta. Of these, 436 deaths (78%) occurred pre-HAART and 124 (22%) in the current HAART period. The crude mortality rate declined from 117 deaths per 1000 patient-years pre-HAART to 24 in the current HAART period. In the pre-HAART era, 90% of all deaths were AIDS related whereas only 67% were AIDS related in the current HAART era. The leading causes of AIDS deaths were AIDS multiple causes (31%), Mycobacterium avium complex (18%), Pneumocystis pneumonia (10%) and non-Hodgkin's lymphoma (7%). The proportion of non-AIDS related deaths increased from 7% pre-HAART to 32% in the current HAART era. Accidental deaths, including drug overdose (29%), suicide (7%) and violence (3%), hepatic disease (19%), non-AIDS related malignancies (19%), and cardiovascular disease (16%) accounted for the majority of non-AIDS related deaths. No deaths directly caused by drug toxicity were found. Overall, 21% of patients who died were antiretroviral (ARV)-naive. A total of 14% of patients dying from AIDS were ARV-naive in contrast to 35% dying from non-HIV related conditions. Of all those dying from AIDS, 23% died<3 months after their initial diagnosis, reflecting late presentation. In the current HAART era, 87% of patients who died from AIDS were extensively treated, reflecting HAART treatment failures due mostly to multiclass drug resistance (42%), inexorable disease progression despite ARV (32%), lack of ability or interest to be maintained on a lifelong HAART programme (21%) and, rarely, drug intolerance (<1%). CONCLUSIONS: Deaths from AIDS-related causes have decreased significantly, but deaths from non-AIDS related conditions have increased, both as an absolute number of deaths and as a proportion of all deaths in HIV-infected patients. The increasing age of the HIV population, and the increased mean CD4 count, increased proportion of intravenous drug users, increased hepatitis B virus and hepatitis C virus coinfection rate, and increased history of smoking seen in our population also influenced the mortality rate and causes of death. These factors must also be considered in projecting future trends in mortality of an HIV-infected population.

The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection.

OBJECTIVE: To compare the direct costs of medical care in the year following HIV diagnosis for patients who present with a CD4 count <200 cells/microL ('late presenters') and those who present with a CD4 count >200 cells/microL ('early presenters'). METHODS: Direct costs (i.e. drugs, laboratory tests, outpatient care, in-patient care, and home care) for the 12 months following HIV diagnosis, sociodemographic data and clinical data were collected for all patients presenting for HIV care in Southern Alberta, Canada between April 1996 and April 2001. Mean costs are presented as costs in 2001 Canadian dollars. RESULTS: Thirty-nine per cent of 241 patients presented with a CD4 count <200 cells/microL. The mean costs for late presenters were more than twice as high as those for early presenters (i.e. $18,448 vs. $8455, respectively). Late presenters were more likely to be older, male and black, and to have a risk activity of men having sex with men (MSM) or heterosexual contact (P<0.05). However, the large difference in mean costs cannot be attributed to differences in characteristics. When characteristics were statistically held constant, the estimated excess cost of late presentation was almost unaffected, at $9723 (z=5.6). Repeating the analysis using disaggregated costing categories suggested that the difference in total costs was largely attributable to differences in HIV-related hospital care costs, which were 15 times higher for late presenters. CONCLUSIONS: Direct care costs in the year following HIV diagnosis were more than 200% higher for patients who presented late. This difference could not be attributed to differences in patient characteristics. Most costs were attributable to HIV-related hospital care costs and the immediate initiation of antiretroviral therapy. While early diagnosis in those at risk for HIV remains medically important, the short-term economic impact is also substantial.

[Measurement of the quality perception by patients subjected to a partial service approach]. / Messung der Qualitätswahrnehmung von Patienten mit teilleistungsbezogenem Ansatz.

The service quality perceived by hospital patients is of increasing economic and moral importance. This paper empirically examines whether a partial service related approach for services with a high complexity is suitable for assessing the quality of a hospital stay. Factor analysis is used as method for analysis. Evidence of the concurrence between a partial service formulation of the quality dimensions and the perception of the patients is presented. A structural relationship suspected between part qualities and the total quality was confirmed.

[Patient satisfaction-subjective quality assessment by patients and success factor for clinics]. / Patientenzufriedenheit-subjektive Qualitätswahrnehmung der Patienten und Erfolgsfaktor für Kliniken.

In the field of measuring patient satisfaction (in other words, the quality perceived subjectively by hospital patients) there is still a great need for more knowledge. Therefore, the Institute of Medical Computer Science and Biometry of the University of Rostock carried out a questioning of 497 patients at the Hospital for Internal Medicine of the University Rostock to measure the patient satisfaction with the hospital. In addition, an employee questioning was performed in order to gain further information. In addition to univariate and bivariate analyses a special focus was set on the analysis of the hospitals' competitive situation, to take into account the importance of patient satisfaction as strategic success factor within the competitive situation. A competition analysis and a Key-Issue Analysis were performed. Finally, focus is on the problems of external hospital comparison and a comparison of trends of patient satisfaction at hospitals in Hamburg and Rostock was made.

Microscopic effects of predator digestion on the surfaces of bones and teeth.

Concentrations of small fossil mammals are frequently encountered in Cenozoic deposits, but the causes for such accumulations have seldom been determined. In many cases the tooth, jaw, and limb fragments appear to be well-preserved under light microscopy, and it is difficult to differentiate damage due to predator digestion from breakage and abrasion due to physical agents. In order to find more specific evidence of predator digestion, we used a scanning electron microscope (SEM) to examine the surface microstructure of bones and teeth consumed by Bubo virginianus (great horned owl) and Canis latrans (coyote), which prey upon similar species. Effects of digestion were found on all the digested bones and teeth examined. The effects on bone include distinctive sets of pits and fissures, dissolution, and physical polishing. The pits and fissures are apparently caused by solution that commences in canals beneath the surface of the bone. The most conspicuous effects on teeth are island-like pillars of dentin surrounded by deep solution fissures. The effects of digestion by coyote and owl are fundamentally the same but differ in degree of development. Bone digested by the owl shows a greater degree of polishing and rounding of edges but has less extensive fissuring. Wide variation in the degree of surface damage occurs in bones digested by the coyote, even within a single fecal pellet.